https://doi.org/10.46344/JBINO.2026.v15i03.07

TRANSFERRIN RECEPTOR EXPRESSION IN BREAST CANCER: DIAGNOSTIC AND THERAPEUTIC INSIGHTS- A NARRATIVE REVIEW

***Emmanuel Ifeanyi Obeagu[1,2]**

[1]Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe
[2]Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

ABSTRACT

Transferrin receptor (TfR) overexpression has emerged as a crucial factor in the progression of breast cancer, playing a pivotal role in regulating iron homeostasis to meet the increased metabolic demands of tumor cells. Iron, essential for DNA synthesis and cellular proliferation, is actively imported into cells via TfR, making it a key regulator of cancer cell growth. This review examines the molecular mechanisms by which TfR expression is upregulated in breast cancer and its impact on tumor development, metastasis, and therapeutic resistance. Beyond its diagnostic utility, TfR overexpression offers novel therapeutic opportunities, particularly in the development of targeted therapies. TfR-targeted drug delivery systems, including antibody-drug conjugates and nanoparticle-based therapies, exploit the receptor's role in iron uptake to selectively deliver cytotoxic agents to breast cancer cells. Additionally, targeting TfR may enhance the effectiveness of ferroptosis-inducing therapies, a form of iron-dependent cell death, providing a promising strategy to overcome treatment resistance. Despite these advancements, challenges such as off-target effects, resistance mechanisms, and toxicity must be addressed for successful clinical implementation of TfR-based therapies.

Keywords: *Transferrin receptor, Breast cancer, Diagnosis, Therapeutics, Targeted therapy*

Introduction

Breast cancer is one of the most common malignancies worldwide, contributing significantly to global morbidity and mortality rates. Despite advances in early detection, treatment, and management strategies, breast cancer remains a major health challenge. A critical aspect of cancer progression is the ability of tumor cells to adapt to their changing environment, particularly in relation to nutrient acquisition. Among these essential nutrients, iron stands out due to its vital role in cellular metabolism, including DNA synthesis, cellular proliferation, and mitochondrial function. Dysregulation of iron metabolism in breast cancer cells has been widely recognized as a key factor in tumor growth and metastasis. Iron acquisition in cancer cells is predominantly mediated by the TfR, a cell-surface protein responsible for importing iron via binding to transferrin, the primary iron transport protein in the bloodstream.[1-2] TfR plays a pivotal role in maintaining intracellular iron homeostasis. Under normal physiological conditions, TfR expression is tightly regulated based on iron availability: low intracellular iron levels stimulate TfR expression to enhance iron uptake, whereas excess iron leads to a reduction in TfR expression. However, in cancer cells, particularly in breast cancer, this regulation is often disrupted, leading to the overexpression of TfR. This overexpression allows cancer cells to acquire large amounts of iron, which are necessary to support their rapid growth and survival in the face of oxidative stress and other tumor-associated challenges. The increased expression of TfR has been linked to aggressive tumor behavior, higher metastatic potential, and poor prognosis, highlighting its importance in breast cancer progression.[3-4] The role of TfR in breast cancer extends beyond iron acquisition. Iron is a critical cofactor in many biological processes, including cell division, oxidative phosphorylation, and DNA synthesis. As breast cancer cells proliferate uncontrollably, their need for iron increases, making the availability of iron a limiting factor in tumor growth. TfR expression facilitates the uptake of iron into these cells, ensuring that they have an adequate supply to fuel their high metabolic demands. Additionally, TfR has been implicated in the regulation of oxidative stress, as iron is also involved in the production of reactive oxygen species (ROS), which, in turn, can promote tumorigenesis. Iron-mediated ROS production can create a microenvironment that supports cancer cell survival, angiogenesis, and metastasis.[5] The diagnostic potential of TfR in breast cancer has been increasingly recognized in recent years. Elevated TfR expression levels in breast cancer tissues and circulating tumor cells make it an attractive biomarker for early diagnosis, prognosis, and therapeutic monitoring. Immunohistochemical analysis of TfR expression can provide valuable insights into the tumor's iron status and its potential for aggressive behavior. High levels of TfR expression are typically associated with more advanced disease stages and poorer patient outcomes, underscoring its role in cancer progression. Furthermore, monitoring TfR expression during treatment may offer a means of assessing

therapeutic efficacy, particularly for therapies targeting iron metabolism.[6] The therapeutic potential of targeting TfR in breast cancer has generated significant interest in recent years. Given its essential role in iron uptake and cancer cell survival, TfR has emerged as a promising target for novel therapeutic interventions. One of the most promising strategies involves the development of TfR-targeted drug delivery systems, where cytotoxic agents are conjugated to transferrin or anti-TfR antibodies. These targeted therapies capitalize on the overexpression of TfR in cancer cells to selectively deliver therapeutic agents, thereby improving drug efficacy while minimizing off-target toxicity. Such approaches have shown promise in preclinical and clinical trials, although challenges remain in optimizing these therapies for clinical use.[7] Another emerging therapeutic strategy involves the induction of ferroptosis, a form of iron-dependent cell death. Ferroptosis is characterized by the accumulation of lipid peroxides and reactive oxygen species (ROS) in the presence of excess intracellular iron. Given TfR's role in regulating intracellular iron levels, targeting this receptor may enhance the susceptibility of breast cancer cells to ferroptosis. By promoting ferroptosis, it may be possible to selectively induce cell death in TfR-overexpressing cancer cells, providing a novel and effective treatment strategy. This approach, however, is still in its early stages and requires further investigation to fully understand its potential in the clinical setting.[8]

Despite the promising therapeutic opportunities, targeting TfR in breast cancer comes with several challenges. One of the main concerns is the potential for off-target effects. While TfR is highly expressed in many cancer cells, it is also present in normal tissues, albeit at lower levels. Targeting TfR without proper specificity may lead to toxicity in healthy tissues, which could limit the therapeutic window. Additionally, the development of resistance mechanisms to TfR-targeted therapies is a potential obstacle. Cancer cells may downregulate TfR expression or activate alternative pathways to maintain iron homeostasis, undermining the effectiveness of TfR-targeted treatments. Addressing these challenges will be crucial for the successful clinical implementation of TfR-targeted therapies.[9] Research into the molecular mechanisms regulating TfR expression in breast cancer is ongoing. Studies have shown that TfR expression is influenced by a variety of factors, including hypoxia, oncogenic signaling pathways, and changes in cellular iron metabolism. The hypoxic tumor microenvironment, for example, can upregulate TfR expression through the activation of hypoxia-inducible factors (HIFs), which are known to play a role in the adaptation of tumors to low-oxygen conditions. Additionally, the activation of oncogenes such as MYC and HER2, which are commonly involved in breast cancer, has been shown to enhance TfR expression, further supporting the role of this receptor in tumor progression.[10] TfR-targeted therapies are still in the experimental stage, with ongoing clinical trials assessing their safety and efficacy. Early-phase trials have demonstrated the potential of TfR-targeted monoclonal

antibodies and antibody-drug conjugates (ADCs) in selectively delivering cytotoxic agents to breast cancer cells. These strategies aim to exploit the overexpression of TfR in tumor cells to improve drug delivery while minimizing systemic side effects. However, as with any new therapeutic approach, challenges such as optimizing dosing regimens, determining the appropriate patient population, and managing resistance mechanisms remain. Further research and clinical testing are needed to refine these therapies and establish their role in the treatment of breast cancer.[11]

Aim

The aim of this review is to explore the role of TfR expression in breast cancer, focusing on its mechanisms, diagnostic implications, and therapeutic potential.

Justification of the Review

The exploration of TfR expression in breast cancer is of considerable importance due to its potential role as both a biomarker and therapeutic target. Iron metabolism, which is tightly regulated within normal cells, is often disrupted in cancer cells to support their rapid growth and survival. TfR, as a key player in cellular iron uptake, is overexpressed in many types of tumors, including breast cancer. This overexpression not only facilitates tumor progression but also presents a unique opportunity to develop targeted diagnostic and therapeutic strategies.[12] Despite the growing interest in TfR-targeted therapies, the current understanding of its expression regulation, functional role in tumorigenesis, and its broader implications in cancer biology remains limited. While several studies have shown promising results in targeting TfR for drug delivery, more research is needed to address issues such as tumor heterogeneity, drug resistance, and the potential for off-target effects. Additionally, the clinical application of TfR-based therapies in breast cancer is still in the early stages, necessitating a thorough review of current findings, challenges, and future directions in this field.[13] This review is therefore timely and necessary, as it aims to provide an in-depth synthesis of the existing literature on TfR in breast cancer, highlighting both its diagnostic and therapeutic potential. By consolidating current knowledge and identifying gaps in the research, this review aims to serve as a valuable resource for clinicians, researchers, and pharmaceutical developers interested in advancing the use of TfR-targeted strategies in breast cancer diagnosis and treatment. Ultimately, this review will contribute to the growing body of evidence supporting TfR as a viable therapeutic target, with the potential to improve patient outcomes and pave the way for personalized, precision-based treatments in breast cancer.

Review Methods

Literature Search Strategy: A thorough literature search was conducted in multiple scientific databases, including PubMed, Scopus, Web of Science, and Google Scholar. Keywords such as "transferrin receptor," "breast cancer," "diagnostic biomarkers," "therapeutic strategies," "targeted therapies," and "iron metabolism" were used in combination to identify relevant studies. The search was restricted to articles published in English between 2000 and 2024. To ensure that the

review included the most up-to-date research, recent studies, clinical trials, and meta-analyses were prioritized.

Inclusion and Exclusion Criteria: Studies were selected based on specific inclusion and exclusion criteria:

- **Inclusion Criteria:**
  - Peer-reviewed original research articles, clinical trials, and systematic reviews.
  - Studies that discussed TfR expression, regulation, or its role in breast cancer.
  - Research exploring TfR-targeted therapies or diagnostic applications in breast cancer.
  - Studies published in English.
- **Exclusion Criteria:**
  - Articles not directly related to TfR or breast cancer.
  - Non-peer-reviewed articles, editorials, or abstracts without full text.
  - Studies focusing on cancers other than breast cancer.

Transferrin Receptor Expression in Breast Cancer

Breast cancer is a heterogeneous disease, with distinct subtypes that vary in their molecular characteristics, clinical behavior, and therapeutic responses. Despite significant advancements in early detection and treatment, breast cancer remains one of the leading causes of cancer-related deaths worldwide. Iron, a crucial element for cellular metabolism, plays a fundamental role in the rapid proliferation and survival of breast cancer cells. Its homeostasis is tightly regulated through multiple mechanisms, one of which involves the TfR, a transmembrane protein responsible for facilitating the uptake of iron bound to transferrin into cells. TfR expression is elevated in many malignancies, including breast cancer, where it is associated with increased tumor progression, metastasis, and resistance to certain therapies.[14]

Mechanisms of Transferrin Receptor Expression in Breast Cancer

Iron is essential for various cellular processes, including DNA replication, cellular respiration, and the synthesis of enzymes involved in metabolism. In breast cancer cells, iron metabolism is frequently dysregulated to meet the heightened metabolic demands of tumor growth. The overexpression of TfR in breast cancer is a key mechanism by which tumor cells secure the increased iron required for their survival and proliferation. TfR is upregulated in response to the low intracellular iron levels that are often present in rapidly dividing cancer cells. This process is primarily regulated by the iron-responsive element (IRE) and iron regulatory proteins (IRPs), which control the translation of TfR mRNA. In breast cancer, this regulatory system is often disrupted, leading to sustained TfR expression even under conditions of iron sufficiency.[15] Beyond the role of iron uptake, TfR is also involved in various signaling pathways that influence breast cancer cell behavior. For instance, TfR has been implicated in the regulation of oxidative stress, a hallmark of cancer cells, which is essential for tumor progression and metastasis. Iron is a critical component in the generation of reactive oxygen species (ROS), and elevated TfR expression in breast cancer cells can result in an accumulation of ROS, promoting

tumorigenesis, angiogenesis, and metastasis. Furthermore, TfR has been shown to interact with other cellular proteins and signaling pathways that enhance cell survival, proliferation, and invasion, further supporting its role in breast cancer progression.[16]

Impact of Transferrin Receptor Expression in Breast Cancer

The expression of TfR in breast cancer has significant implications for both diagnosis and therapy. High levels of TfR expression are often correlated with aggressive tumor behavior, including increased metastatic potential and poor prognosis. Studies have shown that elevated TfR expression is associated with advanced disease stages, lymph node involvement, and reduced survival rates. These associations make TfR a valuable diagnostic biomarker in breast cancer, providing insight into tumor biology and helping to predict clinical outcomes. Furthermore, measuring TfR expression can aid in assessing treatment response, as changes in TfR levels may reflect tumor adaptation to therapeutic interventions, such as chemotherapy or targeted therapy.[17] The therapeutic implications of TfR expression are also substantial. Given its critical role in iron homeostasis, TfR has emerged as a promising target for novel therapeutic strategies in breast cancer. One of the most exciting approaches involves the development of TfR-targeted drug delivery systems. By conjugating cytotoxic agents or chemotherapy drugs to molecules that bind specifically to TfR, such as transferrin or anti-TfR antibodies, it is possible to deliver therapeutic agents directly to tumor cells while minimizing off-target toxicity. This targeted approach has shown promise in preclinical studies, where TfR-targeted therapies selectively inhibited breast cancer cell growth and reduced tumor size. Moreover, TfR-targeted therapies may also enhance the efficacy of existing treatments, such as chemotherapy or radiotherapy, by improving drug delivery to tumor cells.[18] Additionally, TfR-targeted therapies are being explored in combination with ferroptosis, a form of iron-dependent cell death. By increasing iron levels within cancer cells, it is possible to induce ferroptosis, leading to selective cell death in TfR-overexpressing tumor cells. This approach exploits the iron uptake mechanism facilitated by TfR to promote oxidative damage and cell death. As ferroptosis-inducing agents continue to gain attention as potential cancer therapies, targeting TfR offers a new avenue for enhancing ferroptosis and overcoming treatment resistance in breast cancer.[19] Figure 1 shows Transferrin Receptor Expression in Breast Cancer (provided by the authors).

Diagnostic Implications of Transferrin Receptor Expression in Breast Cancer

TfR expression has garnered increasing attention as a diagnostic biomarker in breast cancer due to its role in regulating iron homeostasis and supporting the enhanced metabolic demands of tumor cells. TfR is a membrane glycoprotein responsible for facilitating the transport of iron into cells, particularly in proliferating cells such as those in cancer. Its expression is upregulated in response to iron deficiency and increased metabolic activity, both of which are common in

rapidly dividing tumor cells. Therefore, assessing TfR levels in breast cancer tissues can provide valuable insights into the biological behavior of the tumor and help in determining the prognosis and treatment strategies for patients.[20]

Correlation with Tumor Aggressiveness and Prognosis

Several studies have demonstrated a correlation between elevated TfR expression and more aggressive forms of breast cancer. High levels of TfR are often associated with advanced tumor stages, larger tumor size, and increased metastatic potential, particularly to the lymph nodes. This correlation suggests that TfR could serve as a marker for poor prognosis, helping clinicians stratify patients based on the risk of recurrence and metastasis. In some cases, high TfR expression has been linked to lower overall survival rates, reinforcing its potential value as a prognostic indicator. As a result, monitoring TfR expression may assist in predicting the clinical course of the disease, guiding treatment decisions, and offering a more personalized approach to patient management.[21]

Diagnostic Utility in Early Detection

Beyond its prognostic value, TfR expression may also have diagnostic utility in the early detection of breast cancer. Because TfR is overexpressed in tumor cells compared to normal breast tissue, measuring TfR levels could aid in the identification of early-stage cancers that may otherwise be difficult to detect through conventional imaging or biopsy methods. Additionally, TfR expression may complement other biomarkers, enhancing the sensitivity and specificity of current diagnostic techniques. For instance, combining TfR expression levels with hormone receptor status or HER2 expression could improve the diagnostic accuracy in distinguishing between different breast cancer subtypes. Early detection is crucial for improving outcomes in breast cancer, as the likelihood of successful treatment and survival rates significantly increase when the disease is diagnosed at an early stage.[22]

Non-invasive Diagnostic Approaches

Incorporating TfR as a biomarker also opens the possibility of non-invasive diagnostic methods. Liquid biopsy, which analyzes circulating tumor cells (CTCs), extracellular vesicles, or plasma-derived DNA, could potentially be used to assess TfR expression in a less invasive manner compared to traditional tissue biopsy. Since TfR is often shed into the bloodstream by tumor cells, detecting elevated levels of soluble TfR or TfR-related components in plasma could serve as a non-invasive diagnostic tool. This approach may not only facilitate early detection but also enable continuous monitoring of disease progression, treatment response, and detection of minimal residual disease. The development of such liquid biopsy tests could transform breast cancer diagnostics, offering a more accessible, less painful, and more cost-effective alternative to traditional tissue biopsy methods.[23]

Monitoring Treatment Response and Resistance

TfR expression may also play a role in monitoring the effectiveness of treatment in breast cancer patients. Studies have shown that changes in TfR levels can reflect tumor adaptation to therapeutic

interventions, including chemotherapy, targeted therapy, and immunotherapy. For instance, if TfR expression decreases after treatment, it may indicate that the tumor is responding to therapy. Conversely, if TfR expression persists or increases, it could suggest resistance to treatment, prompting clinicians to consider alternative therapies or investigate the underlying mechanisms of resistance. Furthermore, since TfR is involved in the uptake of iron, a critical component for cellular metabolism and growth, its expression levels may be reflective of the tumor's ability to adapt to altered metabolic environments, a key factor in therapeutic resistance.[24] Figure 2 shows Diagnostic Implications of Transferrin Receptor Expression in Breast Cancer (provided by the authors).

Therapeutic Implications: Targeting Transferrin Receptor in Breast Cancer

TfR plays a critical role in iron homeostasis by mediating the cellular uptake of iron-bound transferrin, a process essential for the rapid proliferation and survival of cells, including cancer cells. In breast cancer, TfR expression is often upregulated in response to the increased metabolic demands of growing tumors. This elevated expression provides a unique therapeutic opportunity for targeted interventions aimed at disrupting iron metabolism in cancer cells. Targeting TfR in breast cancer therapy holds the potential to selectively impair tumor cell survival, inhibit metastasis, and improve the efficacy of existing treatments. Several promising therapeutic strategies, including drug delivery systems, monoclonal antibodies, and combination therapies, are being developed to exploit TfR as a therapeutic target in breast cancer.[25]

TfR-Targeted Drug Delivery Systems

One of the most exciting therapeutic approaches is the development of TfR-targeted drug delivery systems. Given that TfR is overexpressed in many cancer cells, including breast cancer, conjugating cytotoxic drugs or chemotherapy agents to transferrin or anti-TfR antibodies allows for the selective delivery of these agents directly to tumor cells. This method aims to enhance the therapeutic efficacy of drugs while minimizing off-target toxicity in healthy tissues. For example, using transferrin-conjugated nanoparticles or ADCs can increase the accumulation of chemotherapy drugs in tumor cells that overexpress TfR, leading to more effective tumor cell killing. Preclinical studies have shown promising results with this approach, where TfR-targeted drug delivery systems resulted in reduced tumor growth and improved treatment outcomes. Additionally, this strategy may help overcome drug resistance by enhancing the specificity and potency of chemotherapeutic agents.[26]

Monoclonal Antibodies Against TfR

Another therapeutic strategy involves the use of monoclonal antibodies targeting TfR. These antibodies can bind to the extracellular domain of TfR, blocking its interaction with transferrin and preventing iron uptake by cancer cells. By inhibiting iron acquisition, TfR-targeted monoclonal antibodies can limit the availability of iron, which is essential for tumor cell growth and survival. Furthermore, blocking TfR can lead to iron deprivation, resulting in oxidative

stress and ferroptosis, a form of programmed cell death triggered by iron overload. Some monoclonal antibodies against TfR have demonstrated anti-tumor effects in preclinical studies, inducing tumor regression in breast cancer models. However, challenges remain in optimizing these antibodies for clinical use, including ensuring their selectivity and minimizing potential side effects associated with iron depletion in normal tissues.[27]

Combination Therapies with Iron Chelators

Given the importance of iron in tumor cell metabolism, combining TfR-targeted therapies with iron chelation therapy has been explored as a potential approach for treating breast cancer. Iron chelators, which bind to free iron in the bloodstream and tissues, can deplete the available iron pool and disrupt iron-dependent processes, such as DNA synthesis and mitochondrial function. When used in combination with TfR-targeted therapies, iron chelators can further inhibit tumor growth by limiting the iron available for uptake via TfR. This combination strategy may enhance the anti-tumor effects of TfR-targeted therapies and increase their efficacy. For example, studies have shown that combining iron chelators like deferoxamine with TfR-targeted agents can induce cell death in breast cancer cells, suggesting that this dual approach could be more effective than single-agent therapies alone.[28]

Ferroptosis Induction via TfR Targeting

Ferroptosis, a form of iron-dependent cell death characterized by the accumulation of lipid peroxides and reactive oxygen species (ROS), has emerged as a potential therapeutic strategy for targeting cancer cells. Since TfR is responsible for mediating iron uptake into cells, targeting TfR can increase intracellular iron levels, which in turn can trigger ferroptosis. Breast cancer cells with high TfR expression are particularly susceptible to ferroptosis because they rely heavily on iron for growth and survival. By upregulating TfR expression or using TfR-targeted therapies, it is possible to induce ferroptosis selectively in tumor cells, leading to their death. This approach offers a novel way to exploit the iron-dependent vulnerability of breast cancer cells, especially in cases where traditional therapies, such as chemotherapy, have become ineffective due to resistance mechanisms. Research into ferroptosis-inducing agents, in combination with TfR-targeted therapies, holds great promise for improving treatment outcomes in breast cancer.[29]

Overcoming Resistance to Conventional Therapies

One of the challenges in breast cancer treatment is the development of resistance to conventional therapies, including chemotherapy and hormonal therapy. Tumor cells often adapt to treatment by altering their metabolic pathways or upregulating alternative iron acquisition mechanisms. Targeting TfR may offer a way to bypass these resistance mechanisms, as TfR-mediated iron uptake is critical for tumor cell survival, particularly in rapidly dividing cancer cells. Additionally, TfR-targeted therapies may sensitize breast cancer cells to chemotherapy and radiation by enhancing iron accumulation within the tumor, promoting oxidative stress and DNA damage. By disrupting iron homeostasis in

combination with traditional treatment regimens, TfR-targeted therapies could enhance the effectiveness of existing therapies and delay or overcome the development of resistance.[30]

Challenges in Targeting Transferrin Receptor in Breast Cancer

While targeting the TfR in breast cancer offers a promising therapeutic strategy, several challenges must be addressed before these approaches can be successfully translated into clinical practice. These challenges range from issues of specificity and potential toxicity to overcoming the development of resistance. Below are some of the key challenges faced when targeting TfR in breast cancer therapy.

1. Specificity of Targeting TfR in Tumor Cells

One of the primary challenges in targeting TfR is ensuring specificity, as TfR is not only expressed in tumor cells but also in normal cells involved in iron metabolism, such as those in the liver, bone marrow, and spleen. Although TfR expression is upregulated in many cancers, including breast cancer, its presence in normal cells raises concerns about off-target effects and potential toxicity. For instance, TfR-targeted therapies could inadvertently affect normal tissues that also rely on iron for their metabolic functions, leading to adverse side effects. Ensuring that TfR-targeted treatments selectively affect tumor cells while minimizing damage to healthy tissues requires the development of highly specific delivery systems and an understanding of the molecular differences in TfR expression between cancerous and normal cells.[31]

2. Resistance to TfR-Targeted Therapies

Another significant challenge is the potential for tumors to develop resistance to TfR-targeted therapies. Tumor cells can adapt to changes in iron metabolism by upregulating alternative iron uptake mechanisms, such as transferrin-independent pathways or other iron transporters like divalent metal transporter 1 (DMT1) or ferroportin. This could result in tumor cells bypassing the need for TfR-mediated iron import and rendering TfR-targeted therapies less effective over time. Furthermore, TfR expression itself can vary between different stages of breast cancer or in response to treatment, which may complicate the identification of patients who will most benefit from TfR-targeted therapies. Overcoming resistance will require a deeper understanding of the dynamic regulation of iron metabolism in tumors and the development of strategies to target multiple pathways involved in iron homeostasis.[32]

3. Off-Target Toxicity and Side Effects

Targeting TfR in breast cancer may inadvertently affect normal tissues that rely on TfR-mediated iron uptake, leading to potential side effects. For example, normal cells in the liver and bone marrow, which play a crucial role in iron storage and erythropoiesis, express TfR at lower levels. However, disrupting the function of these cells could result in systemic iron dysregulation, anemia, or other metabolic disturbances. Furthermore, the potential for oxidative stress resulting from impaired iron homeostasis could cause toxicity in normal tissues, leading to undesirable outcomes. Strategies to limit off-target effects, such as using highly specific monoclonal antibodies or conjugating therapeutic

agents to tumor-specific ligands, will be essential to mitigate these risks.[33]

4. Tumor Heterogeneity and Biomarker Identification

Breast cancer is a highly heterogeneous disease, with various subtypes exhibiting different patterns of TfR expression. Some breast tumors may not overexpress TfR at all, making them less likely to respond to TfR-targeted therapies. Additionally, variations in TfR expression can occur within different regions of the same tumor, making it difficult to predict the overall effectiveness of such therapies. Identifying reliable biomarkers that can accurately predict which patients will benefit from TfR-targeted treatments is crucial for personalizing therapy and improving patient outcomes. Advanced imaging techniques, liquid biopsy methods, and molecular profiling could help identify breast cancer subtypes with high TfR expression and refine patient selection for TfR-based therapies.[34]

5. Development of Effective Drug Delivery Systems

Effective drug delivery is a major challenge in TfR-targeted therapy. While targeting TfR on tumor cells using conjugated cytotoxic agents, nanoparticles, or monoclonal antibodies offers great potential, ensuring the efficient delivery and release of therapeutic agents at the tumor site remains a significant hurdle. Nanoparticles or antibody-drug conjugates (ADCs) must be engineered to achieve high selectivity, stability in circulation, and efficient internalization by TfR-overexpressing cells. Furthermore, tumor cells can often develop mechanisms to evade drug delivery or pump out therapeutic agents, reducing the efficacy of these treatments. Developing novel drug delivery platforms that can overcome these barriers, such as smart nanoparticles or dual-targeting strategies, is crucial for improving the therapeutic efficacy of TfR-targeted therapies.[35]

6. Toxicity of Iron Chelators and Combination Therapies

Iron chelation therapy, when combined with TfR-targeted treatments, offers a promising strategy for further inhibiting tumor growth by depleting available iron in tumor cells. However, the use of iron chelators can also pose significant risks. Prolonged or excessive iron chelation may lead to systemic iron deficiency, resulting in anemia, organ dysfunction, or other metabolic complications. In addition, iron chelators can have off-target effects, potentially interfering with normal cellular functions in non-tumor tissues. Therefore, a careful balance must be struck between using iron chelators to enhance the effects of TfR-targeted therapies while minimizing adverse side effects. The development of more selective and less toxic chelators, as well as optimizing dosing schedules, will be critical in harnessing the full therapeutic potential of combination therapies.[36]

7. Preclinical and Clinical Validation

While preclinical studies have demonstrated the potential of TfR-targeted therapies in breast cancer models, translating these findings into clinical practice remains a challenge. Many promising preclinical results have not yet been confirmed in clinical trials, and the effectiveness of TfR-targeted therapies in humans has yet to be fully established. Variations in the biological response to

these therapies among individual patients, coupled with the complexities of tumor microenvironments and immune responses, make it difficult to predict clinical outcomes. Rigorous clinical validation through well-designed trials is essential to assess the safety, efficacy, and long-term effects of TfR-targeted therapies in breast cancer patients. Additionally, biomarker-driven studies will be necessary to ensure that only patients most likely to benefit from these therapies are selected.[37]

Future Directions in Targeting Transferrin Receptor (TfR) in Breast Cancer Therapy

The field of TfR-targeted therapy in breast cancer holds significant potential, yet several research avenues need exploration to overcome the current limitations and optimize treatment outcomes. As research progresses, the following future directions may further enhance the efficacy and clinical applicability of TfR-targeted therapies in breast cancer.

1. Development of More Selective and Potent TfR-Targeted Therapies

While TfR-targeted therapies, such as monoclonal antibodies (mAbs) and ADCs, have shown promise in preclinical studies, the next step is to develop more selective and potent therapies that can precisely target tumor cells overexpressing TfR. Future research should focus on optimizing the affinity and specificity of antibodies or small molecules that bind to TfR. Additionally, engineering next-generation conjugates that combine high-potency cytotoxic agents with TfR-targeting molecules will enhance therapeutic efficacy and minimize off-target effects. This could involve using newer antibody classes, such as bispecific antibodies, that can bind to TfR and other tumor-specific markers simultaneously, providing a more targeted and effective treatment.[38]

2. Overcoming Tumor Heterogeneity and Dynamic Expression of TfR

Tumor heterogeneity remains a major challenge in cancer therapy, particularly with respect to the varying expression levels of TfR in different subtypes of breast cancer. Research should focus on understanding the dynamic regulation of TfR expression in response to different microenvironments and treatment conditions. Investigating the molecular pathways that regulate TfR expression, including transcriptional and post-transcriptional mechanisms, will allow for more precise targeting of tumors that exhibit fluctuating TfR levels. Additionally, biomarker identification techniques, such as liquid biopsies or advanced imaging, could help predict which patients would most benefit from TfR-targeted therapies and enable real-time monitoring of TfR expression levels throughout the course of treatment.[39]

3. Overcoming Drug Resistance Mechanisms

The development of resistance to TfR-targeted therapies is a significant challenge, as tumor cells can adapt by upregulating alternative iron acquisition mechanisms or reducing TfR expression. Future strategies should focus on overcoming resistance by targeting complementary pathways involved in iron metabolism. For example, inhibiting other iron transporters like DMT1 or ferroportin in combination with TfR-targeted therapies may enhance their efficacy. Another

potential approach is to combine TfR-targeted therapies with agents that disrupt iron storage and recycling pathways within tumor cells, such as targeting ferritin or hepcidin. Additionally, personalized treatment regimens that monitor resistance biomarkers may allow for early detection of therapy failure and timely adjustments to the treatment plan.[40]

4. Investigating Combination Therapies

Combining TfR-targeted therapies with other treatment modalities, such as chemotherapy, immunotherapy, or targeted small molecule inhibitors, could improve treatment outcomes and minimize resistance. For instance, combining TfR-targeted therapies with chemotherapeutic agents that disrupt DNA replication or repair may enhance the cytotoxic effects on tumor cells by depriving them of essential iron. Moreover, combining TfR-targeted therapies with immune checkpoint inhibitors could potentially stimulate the immune system to more effectively target tumor cells, especially those with high TfR expression. Developing these combination therapies will require a deep understanding of the molecular mechanisms underlying tumor response to different therapeutic agents and how these agents interact with TfR-related pathways.[41]

5. Personalized Medicine and Patient Selection

To maximize the benefits of TfR-targeted therapies, future research should focus on personalized medicine strategies, including patient selection based on genetic, molecular, and immunological profiling. Tumor profiling methods, such as transcriptomic and proteomic analyses, can identify patients whose breast cancers exhibit high TfR expression and are more likely to respond to these therapies. Additionally, understanding the immune landscape of tumors with high TfR expression may provide insights into how to better incorporate immune therapies into TfR-targeted regimens. Liquid biopsies, which allow for non-invasive assessment of tumor markers, may also be employed to track changes in TfR expression during treatment and inform adaptive therapy approaches.[38]

6. Advances in Drug Delivery Systems

The effectiveness of TfR-targeted therapies depends significantly on the delivery system used to administer therapeutic agents. Future advancements in nanotechnology and drug delivery systems could enhance the precision and efficacy of TfR-targeted therapies. Nanoparticles and liposomes designed to specifically deliver drugs or RNA-based therapies to TfR-overexpressing tumor cells offer the potential for more efficient drug accumulation at the tumor site, reducing systemic toxicity. Moreover, developing delivery systems that can overcome barriers such as drug efflux pumps or immune evasion mechanisms will be crucial for improving therapeutic outcomes. Smart nanoparticles that release their payload in response to the tumor's microenvironmental signals, such as pH or enzyme activity, represent a promising direction for optimizing drug delivery in TfR-targeted therapies.[39]

7. Investigating the Role of TfR in Tumor Microenvironment

The tumor microenvironment plays a crucial role in modulating the efficacy of

cancer therapies. Future research should focus on investigating the role of TfR not only in cancer cells but also in other components of the tumor microenvironment, including endothelial cells, stromal cells, and immune cells. TfR is known to be involved in regulating immune cell function, and its expression may influence the interaction between tumor cells and immune cells within the tumor microenvironment. Targeting TfR on both cancer cells and immune cells could enhance the immune response to tumors and improve the efficacy of immunotherapies. Additionally, studying the crosstalk between TfR expression and other immune checkpoint pathways may reveal new strategies for overcoming resistance to therapy.[40]

8. Evaluating Long-Term Effects and Safety

Finally, as TfR-targeted therapies move from preclinical studies into clinical trials, it will be essential to evaluate the long-term effects and safety profiles of these therapies. While short-term efficacy is a critical aspect, understanding the potential for cumulative toxicity, immune modulation, and secondary health impacts will be vital. Iron homeostasis in the body is tightly regulated, and disrupting this balance over prolonged periods could lead to iron overload, oxidative stress, or organ dysfunction. Long-term monitoring of iron levels and organ health will be necessary to ensure the safety of TfR-targeted therapies, especially in combination with other treatments.[41]

Conclusion

TfR expression in breast cancer has emerged as a critical area of investigation, offering valuable diagnostic and therapeutic insights. The upregulation of TfR in breast cancer cells, driven by the tumor's increased demand for iron, highlights its potential as both a biomarker for early detection and a target for novel therapeutic strategies. Despite significant progress in understanding the mechanisms underlying TfR expression, much remains to be explored in terms of its regulation, its impact on tumor biology, and its interaction with other components of the tumor microenvironment. Targeting TfR in breast cancer presents exciting therapeutic potential, particularly through approaches such as monoclonal antibodies, antibody-drug conjugates, and small molecules. However, challenges such as tumor heterogeneity, drug resistance, and potential off-target effects need to be addressed to optimize the efficacy and safety of TfR-targeted therapies. Additionally, exploring combination therapies, personalized medicine, and advanced drug delivery systems will be critical for overcoming these obstacles and improving patient outcomes.

List of Abbreviations

ADCs - antibody-drug conjugates
CTCs - circulating tumor cells
DMT1- divalent metal transporter 1
IRE - iron-responsive element
IRPs - iron regulatory proteins
mAbs - monoclonal antibodies
TfR - Transferrin receptor
ROS - reactive oxygen species

References

1. Torti SV, Torti FM. Cellular iron metabolism in prognosis and therapy of breast cancer.

Critical Reviews™ in Oncogenesis. 2013;18(5).
2. Morales M, Xue X. Targeting iron metabolism in cancer therapy. Theranostics. 2021; 11(17):8412.
3. Wang Y, Yu L, Ding J, Chen Y. Iron metabolism in cancer. International journal of molecular sciences. 2018; 20(1):95.
4. Brown RA, Richardson KL, Kabir TD, Trinder D, Ganss R, Leedman PJ. Altered iron metabolism and impact in cancer biology, metastasis, and immunology. Frontiers in oncology. 2020; 10:476.
5. Hsu MY, Mina E, Roetto A, Porporato PE. Iron: an essential element of cancer metabolism. Cells. 2020; 9(12):2591.
6. Chen Y, Fan Z, Yang Y, Gu C. Iron metabolism and its contribution to cancer. International journal of oncology. 2019; 54(4):1143-1154.
7. Islam S, Hoque N, Nasrin N, Hossain M, Rizwan F, Biswas K, Asaduzzaman M, Rahman S, Hoskin DW, Sultana S, Lehmann C. Iron overload and breast cancer: iron chelation as a potential therapeutic approach. Life. 2022; 12(7):963.
8. Scimeca M, Bonanno E. New highlight in breast cancer development: the key role of hepcidin and iron metabolism. Annals of Translational Medicine. 2018; 6(Suppl 1).
9. Zhou L, Zhao B, Zhang L, Wang S, Dong D, Lv H, Shang P. Alterations in cellular iron metabolism provide more therapeutic opportunities for cancer. International journal of molecular sciences. 2018; 19(5):1545.
10. Lin HY, Ho HW, Chang YH, Wei CJ, Chu PY. The evolving role of ferroptosis in breast cancer: translational implications present and future. Cancers. 2021; 13(18):4576.
11. Heath JL, Weiss JM, Lavau CP, Wechsler DS. Iron deprivation in cancer—potential therapeutic implications. Nutrients. 2013; 5(8):2836-2859.
12. Pogribny IP, Tryndyak VP, Pogribna M, Shpyleva S, Surratt G, Gamboa da Costa G, Beland FA. Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents. International journal of oncology. 2013; 42(5):1822-1832.
13. Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochimica et Biophysica Acta (BBA)-General Subjects. 2009; 1790(7):702-717.
14. Marques O, da Silva BM, Porto G, Lopes C. Iron homeostasis in breast cancer. Cancer letters. 2014; 347(1):1-4.
15. Torti SV, Torti FM. Cellular iron metabolism in prognosis and therapy of breast cancer. Critical Reviews™ in Oncogenesis. 2013;18(5).
16. Marques O, da Silva BM, Porto G, Lopes C. Iron homeostasis in breast cancer. Cancer letters. 2014 May 28; 347(1):1-4.
17. Chen C, Liu P, Duan X, Cheng M, Xu LX. Deferoxamine-induced high expression of TfR1 and DMT1 enhanced iron uptake in triple-negative breast cancer cells by activating IL-6/PI3K/AKT pathway. OncoTargets and therapy. 2019:4359-4377.
18. Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard-Davenport A, Chekhun VF, Beland FA, Pogribny IP. Role of ferritin alterations in

human breast cancer cells. Breast cancer research and treatment. 2011; 126:63-71.
19. Alkhateeb AA, Han B, Connor JR. Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages. Breast cancer research and treatment. 2013; 137:733-744.
20. Shibabaw T, Teferi B, Molla MD, Ayelign B. Inflammation mediated hepcidin-ferroportin pathway and its therapeutic window in breast cancer. Breast Cancer: Targets and Therapy. 2020:165-180.
21. Pinnix ZK, Miller LD, Wang W, D'Agostino Jr R, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV. Ferroportin and iron regulation in breast cancer progression and prognosis. Science translational medicine. 2010; 2(43):43ra56-.
22. Le Y, Liu Q, Yang Y, Wu J. The emerging role of nuclear receptor coactivator 4 in health and disease: a novel bridge between iron metabolism and immunity. Cell Death Discovery. 2024; 10(1):312.
23. Santana-Codina N, Del Rey MQ, Kapner KS, Zhang H, Gikandi A, Malcolm C, Poupault C, Kuljanin M, John KM, Biancur DE, Chen B. NCOA4-mediated ferritinophagy is a pancreatic cancer dependency via maintenance of iron bioavailability for iron–sulfur cluster proteins. Cancer discovery. 2022; 12(9):2180-2197.
24. Bystrom LM, Guzman ML, Rivella S. Iron and reactive oxygen species: friends or foes of cancer cells?. Antioxidants & redox signaling. 2014; 20(12):1917-1924.
25. Mittler R, Darash-Yahana M, Sohn YS, Bai F, Song L, Cabantchik IZ, Jennings PA, Onuchic JN, Nechushtai R. NEET proteins: a new link between iron metabolism, reactive oxygen species, and cancer. Antioxidants & redox signaling. 2019; 30(8):1083-1095.
26. Battaglia AM, Chirillo R, Aversa I, Sacco A, Costanzo F, Biamonte F. Ferroptosis and cancer: mitochondria meet the "iron maiden" cell death. Cells. 2020; 9(6):1505.
27. Wu ZH, Tang Y, Yu H, Li HD. The role of ferroptosis in breast cancer patients: a comprehensive analysis. Cell death discovery. 2021; 7(1):93.
28. Ma S, Fu X, Liu L, Liu Y, Feng H, Jiang H, Liu X, Liu R, Liang Z, Li M, Tian Z. Iron-dependent autophagic cell death induced by radiation in MDA-MB-231 breast cancer cells. Frontiers in Cell and Developmental Biology. 2021; 9:723801.
29. Brown RA, Richardson KL, Kabir TD, Trinder D, Ganss R, Leedman PJ. Altered iron metabolism and impact in cancer biology, metastasis, and immunology. Frontiers in oncology. 2020; 10:476.
30. Sacco A, Battaglia AM, Botta C, Aversa I, Mancuso S, Costanzo F, Biamonte F. Iron metabolism in the tumor microenvironment—Implications for anti-cancer immune response. Cells. 2021; 10(2):303.
31. Kontoghiorghes GJ. New iron metabolic pathways and chelation targeting strategies affecting the treatment of all types and stages of cancer. International Journal of Molecular Sciences. 2022; 23(22):13990.
32. El Hout M, Dos Santos L, Hamaï A, Mehrpour M. A promising new approach to cancer therapy: targeting iron metabolism in cancer stem cells. InSeminars in Cancer Biology 2018; 53: 125-138. Academic Press.
33. Buss JL, Torti FM, Torti SV. The role of iron chelation in cancer therapy. Current

medicinal chemistry. 2003; 10(12):1021-1034.
34. Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P. Transferrin receptor 1 in cancer: a new sight for cancer therapy. American journal of cancer research. 2018; 8(6):916.
35. Tortorella S, Karagiannis TC. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. The Journal of membrane biology. 2014; 247:291-307.
36. Feng J, Wang ZX, Bin JL, Chen YX, Ma J, Deng JH, Huang XW, Zhou J, Lu GD. Pharmacological approaches for targeting lysosomes to induce ferroptotic cell death in cancer. Cancer Letters. 2024; 587:216728.
37. Zhao X, Wang X, Pang Y. Phytochemicals targeting ferroptosis: therapeutic opportunities and prospects for treating breast cancer. Pharmaceuticals. 2022; 15(11):1360.
38. Pogribny IP. Ferroportin and hepcidin: a new hope in diagnosis, prognosis, and therapy for breast cancer. Breast Cancer Research. 2010; 12:1-2.
39. Hosseinkazemi H, Samani S, O'Neill A, Soezi M, Moghoofei M, Azhdari MH, Aavani F, Nazbar A, Keshel SH, Doroudian M. Applications of iron oxide nanoparticles against breast cancer. Journal of Nanomaterials. 2022; 2022(1):6493458.
40. Saeed M, Ren W, Wu A. Therapeutic applications of iron oxide based nanoparticles in cancer: basic concepts and recent advances. Biomaterials science. 2018; 6(4):708-725.
41. Tury S, Assayag F, Bonin F, Chateau-Joubert S, Servely JL, Vacher S, Becette V, Caly M, Rapinat A, Gentien D, De La Grange P. The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers. The Journal of pathology. 2018; 246(1):103-114.